Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A compound represented by Formula I:



wherein R^1 and R^2 are independently chosen from hydrogen or an alkyl group;

R^3 and R^4 are independently hydrogen or an alkyl group or;

R^3 and R^4 and the carbon atom to which they are attached form a cycloalkyl ring, or;

R^2 and R^3 together form a saturated $(CH_2)_m$ heterocycle;

R^5 is hydrogen, halogen, or a substituted or unsubstituted alkyl group;

R^6 and R^7 are independently hydrogen, halogen, cyano, an alkylthio, or a substituted or unsubstituted alkyl group;

R^8 and R^9 are independently hydrogen, hydroxyl, a substituted or unsubstituted alkyl group, an alkoxy, =O, $NR^{10}R^{11}$, $OC(=O)NR^1R^2$, $OC(=O)C_{1\text{-}4}$alkyl, or an alkylthiol;

R^{10} and R^{11} are independently hydrogen, a substituted or unsubstituted alkyl group, $C(=O)C_{1\text{-}4}$ alkyl, $C(=O)OC_{1\text{-}4}$ alkyl, or $C(=O)NR^1R^2$ or R^{10} and R^{11} together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is $(CH_2)_n$, C=O, or $CHC_{1\text{-}4}$alkyl;

B is either a single or a double bond, wherein when B is a double bond, R^8 and R^9 are selected from hydrogen, or a substituted or unsubstituted alkyl group;

m = 2-4;

n = 0-2;

X and Y are either N or C, wherein X and Y are different; and the dashed bonds denote a suitably appointed single and double bond.

Claim 2 (original): The compound of claim 1, wherein R^2 and R^3 form a saturated $(CH_2)_m$ heterocycle.

Claim 3 (original): The compound of claim 1, wherein said R^3 and R^4 together form a cyclopropyl ring.

Claim 4 (original): The compound of claim 1, wherein R^1 and R^2 are independently chosen from hydrogen or C_{1-4}alkyl;

R^3 and R^4 are independently chosen from hydrogen or C_{1-4}alkyl, or R^2 and R^3 together form a saturated $(CH_2)_m$ heterocycle;

R^5 is chosen from hydrogen, halogen, or C_{1-6}alkyl;

R^6 and R^7 are independently chosen from hydrogen, halogen, cyano, C_{1-4}alkylthio, C_{1-4}alkyl, or C_{1-4}alkyl substituted by halogen;

R^8 and R^9 are chosen from hydrogen, hydroxyl, C_{1-6}alkyl, C_{1-6}alkoxy, $NR^{10}R^{11}$, or C_{1-6}alkyl substituted with halogen, hydroxyl, or $NR^{10}R^{11}$;

R^{10} and R^{11} are independently chosen from hydrogen or C_{1-4}alkyl or $C(=O)C_{1-4}$alkyl or R^{10} and R^{11} together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is $(CH_2)_n$ or CHC_{1-4}alkyl;

B is either a single or double bond, wherein when B is a double bond, R^8 and R^9 are selected from hydrogen, C_{1-4}alkyl, or C_{1-4}alkyl substituted by halogen, hydroxy, or $NR^{10}R^{11}$;

m = 3-4;

n = 1-2; and

X and Y are either N or C, wherein X and Y cannot be the same; and

the dashed bonds denote a suitably appointed single and double bond.

Claim 5 (original): The compound of claim 1, wherein R^1 and R^2 are independently chosen from hydrogen or C_{1-4}alkyl;

R^3 is C_{1-2}alkyl, or R^2 and R^3 together are $(CH_2)_3$ to form pyrrolidine;

R^4 is hydrogen;

R^5 is chosen from hydrogen or C_{1-6}alkyl;

R^6 and R^7 are independently chosen from hydrogen, halogen, or C_{1-4}alkyl;

R^8 and R^9 are independently chosen from hydrogen, hydroxyl, C_{1-6}alkoxy, $NR^{10}R^{11}$, or C_{1-6}alkyl substituted with hydroxyl or $NR^{10}R^{11}$;

R^{10} and R^{11} are independently chosen from hydrogen, C_{1-4}alkyl or $C(=O)C_{1-4}$alkyl or R^{10} and R^{11} together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is $(CH_2)_n$;

B is a single bond;

n = 1;

X is C and Y is N; and

the dashed bonds denote a suitably appointed single and double bond.

Claim 6 (original): The compound of claim 1, wherein said compound is:

1-(2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

(S)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-((S)-2-Aminopropyl)-3-methyl-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-(S)-1-Pyrrolidin-2-ylmethyl-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-((S)-2-Aminopropyl)-5-fluoro-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ylamine;

[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-yl]-dimethylamine;

[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-yl]-methanol;

1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazole-8,9-diol;

1-((S)-2-Aminopropyl)-9-methoxy-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-(2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;

1-(Pyrrolidin-2-ylmethyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;

1-((S)-2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;

1-((S)-2-Aminopropyl)-3-methyl-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol; or combinations thereof.

Claim 7 (original): The compound of claim 1, wherein said X is N.

Claim 8 (original): The compound of claim 1, wherein said X is C.

Claim 9 (original): A method of controlling normal or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one compound of claim 1.

Claim 10 (original): The method of claim 9, wherein R^2 and R^3 form a saturated $(CH_2)_m$ heterocycle.

Claim 11 (original): The method of claim 9, wherein said R^3 and R^4 together form a cyclopropyl ring.

Claim 12 (original): The method of claim 9, wherein R^1 and R^2 are independently chosen from hydrogen or C_{1-4}alkyl;

R^3 and R^4 are independently chosen from hydrogen or C_{1-4}alkyl, or R^2 and R^3 together form a saturated $(CH_2)_m$ heterocycle;

R^5 is chosen from hydrogen, halogen, or C_{1-6}alkyl;

R^6 and R^7 are independently chosen from hydrogen, halogen, cyano, C_{1-4}alkylthio, C_{1-4}alkyl, or C_{1-4}alkyl substituted by halogen;

R^8 and R^9 are chosen from hydrogen, hydroxyl, C_{1-6}alkyl, C_{1-6}alkoxy, $NR^{10}R^{11}$, or C_{1-6}alkyl substituted with halogen, hydroxyl, or $NR^{10}R^{11}$;

R^{10} and R^{11} are independently chosen from hydrogen or C_{1-4}alkyl or $C(=O)C_{1-4}$alkyl or R^{10} and R^{11} together can complete a saturated 5 or 6-membered heterocyclic ring, which can include an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is $(CH_2)_n$ or CHC_{1-4}alkyl;

B is either a single or double bond, wherein when B is a double bond, R^8 and R^9 are selected from hydrogen, C_{1-4}alkyl, or C_{1-4}alkyl substituted by halogen, hydroxy, or $NR^{10}R^{11}$;

m = 3-4;

n = 1-2; and

X and Y are either N or C, wherein X and Y cannot be the same; and

the dashed bonds denote a suitably appointed single and double bond.

Claim 13 (original): The method of claim 9, wherein R^1 and R^2 are independently chosen from hydrogen or C_{1-4}alkyl;

R^3 is C_{1-2}alkyl, or R^2 and R^3 together are $(CH_2)_3$ to form pyrrolidine;

R^4 is hydrogen;

R^5 is chosen from hydrogen or C_{1-6}alkyl;

R^6 and R^7 are independently chosen from hydrogen, halogen, or C_{1-4}alkyl;

R^8 and R^9 are independently chosen from hydrogen, hydroxyl, C_{1-6}alkoxy, $NR^{10}R^{11}$, or C_{1-6}alkyl substituted with hydroxyl or $NR^{10}R^{11}$;

R^{10} and R^{11} are independently chosen from hydrogen, C_{1-4}alkyl or $C(=O)C_{1-4}$alkyl or R^{10} and R^{11} together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is $(CH_2)_n$;

B is a single bond;

n = 1;

X is C and Y is N; and

the dashed bonds denote a suitably appointed single and double bond.

Claim 14 (original): The method of claim 9, wherein said compound is:

1-(2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

(S)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-((S)-2-Aminopropyl)-3-methyl-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-(S)-1-Pyrrolidin-2-ylmethyl-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-((S)-2-Aminopropyl)-5-fluoro-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ylamine;

[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-yl]-dimethylamine;

[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-yl]-methanol;

1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazole-8,9-diol;

1-((S)-2-Aminopropyl)-9-methoxy-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-(2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;

1-(Pyrrolidin-2-ylmethyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;

1-((S)-2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;

1-((S)-2-Aminopropyl)-3-methyl-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol; or combinations thereof.

Claim 15 (original): The method of claim 9, wherein said X is N.

Claim 16 (original): The method of claim 9, wherein said X is C.

Claim 17 (original): A method for the treatment of glaucoma comprising administering a pharmaceutically effective amount of a composition comprising at least one compound of claim 1.

Claim 18 (original): The method of claim 17, wherein R^1 and R^2 are independently chosen from hydrogen or C_{1-4}alkyl;

R^3 and R^4 are independently chosen from hydrogen or C_{1-4}alkyl, or R^2 and R^3 together form a saturated $(CH_2)_m$ heterocycle;

R^5 is chosen from hydrogen, halogen, or C_{1-6}alkyl;

R^6 and R^7 are independently chosen from hydrogen, halogen, cyano, C_{1-4}alkylthio, C_{1-4}alkyl, or C_{1-4}alkyl substituted by halogen;

R^8 and R^9 are chosen from hydrogen, hydroxyl, C_{1-6}alkyl, C_{1-6}alkoxy, $NR^{10}R^{11}$, or C_{1-6}alkyl substituted with halogen, hydroxyl, or $NR^{10}R^{11}$;

R^{10} and R^{11} are independently chosen from hydrogen or C_{1-4}alkyl or $C(=O)C_{1-4}$alkyl or R^{10} and R^{11} together can complete a saturated 5 or 6-membered heterocyclic ring, which can include an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is $(CH_2)_n$ or CHC_{1-4}alkyl;

B is either a single or double bond, wherein when B is a double bond, R^8 and R^9 are selected from hydrogen, C_{1-4}alkyl, or C_{1-4}alkyl substituted by halogen, hydroxy, or $NR^{10}R^{11}$;

m = 3-4;

n = 1-2; and

X and Y are either N or C, wherein X and Y cannot be the same; and

the dashed bonds denote a suitably appointed single and double bond.

Claim 19 (original): The method of claim 17, wherein R^1 and R^2 are independently chosen from hydrogen or C_{1-4}alkyl;

R^3 is C_{1-2}alkyl, or R^2 and R^3 together are $(CH_2)_3$ to form pyrrolidine;

R^4 is hydrogen;

R^5 is chosen from hydrogen or C_{1-6}alkyl;

R^6 and R^7 are independently chosen from hydrogen, halogen, or C_{1-4}alkyl;

R^8 and R^9 are independently chosen from hydrogen, hydroxyl, C_{1-6}alkoxy, $NR^{10}R^{11}$, or C_{1-6}alkyl substituted with hydroxyl or $NR^{10}R^{11}$;

R^{10} and R^{11} are independently chosen from hydrogen, C_{1-4}alkyl or $C(=O)C_{1-4}$alkyl or R^{10} and R^{11} together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is $(CH_2)_n$;

B is a single bond;

n = 1;

X is C and Y is N; and

the dashed bonds denote a suitably appointed single and double bond.

Claim 20 (original): The method of claim 17, wherein said compound is:

1-(2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

(S)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-((S)-2-Aminopropyl)-3-methyl-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-(S)-1-Pyrrolidin-2-ylmethyl-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-((S)-2-Aminopropyl)-5-fluoro-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ylamine;

[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-yl]-dimethylamine;

[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-yl]-methanol;

1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazole-8,9-diol;

1-((S)-2-Aminopropyl)-9-methoxy-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;

1-(2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;

1-(Pyrrolidin-2-ylmethyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;

1-((S)-2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;

1-((S)-2-Aminopropyl)-3-methyl-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol; or combinations thereof.

Claim 21 (original): A pharmaceutical composition comprising the compound of claim 1 and at least one carrier.

Claim 22 (currently amended): A method to ~~block~~ activate or bind to serotonin receptors comprising administering an effective amount of at least one compound of claim 1 to a patient.